Application of Panax notoginseng extract in preparing medicine for promoting skin wound repair

Through the preparation and application of bamboo ginseng extract, the problems of low efficiency and insufficient safety of skin trauma healing in the prior art are solved, and the production of collagen and reduced inflammatory response are achieved, and the effect of skin trauma repair is significantly improved.

CN117860797BActive Publication Date: 2024-11-26CHINA THREE GORGES UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311826980.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-27
Publication Date
2024-11-26
Estimated Expiration
2043-12-27

AI Technical Summary

Technical Problem

The prior art lacks effective drugs to accelerate skin trauma healing, and physical therapy is unclear or has side effects, resulting in challenges in the treatment of skin trauma.

Method used

Bamboo ginseng extract is prepared by crushing, ethanol extraction, n-butanol extraction and acetone washing. It is used as a skin trauma repair drug to promote collagen production and proliferation and migration of keratinocytes, and reduce inflammation. reaction.

Benefits of technology

Bamboo ginseng extract can accelerate skin wound healing, promote collagen production and reduce inflammatory response, significantly improve the repair efficiency of skin trauma, and has good biocompatibility and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117860797B_ABST
    Figure CN117860797B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of biomedicine technology, and discloses an application of a bamboo ginseng extract in preparing a drug for promoting skin wound repair. The present invention provides a new application of a bamboo ginseng extract in preparing a drug for promoting skin wound repair, and provides a new natural drug for treating skin wounds. Test results show that the bamboo ginseng extract can promote the healing of acute skin wounds by anti-inflammatory, accelerating the production of collagen in skin lesions, and promoting the proliferation and migration of keratinocytes. Therefore, the drug with the bamboo ginseng extract as an effective ingredient has a good therapeutic effect on skin wounds.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biomedicine, and in particular to an application of a Panax notoginseng extract in preparing a medicine for promoting skin wound repair. Background Art

[0002] Skin trauma is a common and frequently occurring disease in clinical practice, which is caused by external factors (such as mechanical factors, temperature, electricity, radiation and chemical factors) that damage the structure or function of human tissues or organs. With the continuous growth of the global population and the increase of various accidents, skin trauma continues to be prevalent worldwide.

[0003] The skin has multiple layers and can be divided into the epidermis, dermis, and subcutaneous tissue. The outermost layer of mammalian skin is the epidermis, which is an important barrier to maintain life. The most abundant cells in the epidermis (about 90%) are keratinocytes (HaCat), which are mainly composed of basal layer cells that divide and migrate to the epidermis through the granular layer to restore epithelialization. The dermis is composed of extracellular matrix (ECM), blood vessels, nerve endings, sebaceous glands, sweat glands, hair follicles, vascular endothelial cells, and fibroblasts; fibroblasts are an important component of dermal tissue. Dermal fibroblasts are activated by skin damage, and the subsequent proliferation, migration, differentiation, synthesis of extracellular matrix including collagen, and secretion of various cytokines and other biological behaviors are the basis for wound repair. The deepest layer of the skin is the subcutaneous tissue, which is composed of loose connective tissue, fat-storing cells, blood vessels, and nerves.

[0004] Skin wound repair is a complex, multi-step regeneration process after injury. At present, the main clinical methods for treating trauma are suture, debridement and anti-infection treatment measures, but there is still a lack of effective methods to accelerate wound healing and active substances that can safely and effectively stimulate wound repair. Although recent studies have reported that a variety of growth factors can promote wound healing, these substances are expensive, and the dosage and safety issues are difficult to grasp; physical therapies such as microwaves, infrared rays, lasers, etc. have factors such as pigmentation, allergies and unclear efficacy, which are not conducive to patient acceptance. Therefore, the development of drugs that can promote skin wound healing has always been a focus of attention in the field of trauma.

[0005] Bamboo Ginseng is warm in nature, sweet and slightly bitter in taste, and enters the liver, spleen, and lung meridians. It has the effects of nourishing and strengthening, dispersing blood stasis and relieving pain, stopping bleeding, and removing phlegm. Modern pharmacological studies have shown that Bamboo Ginseng has multiple biological activities. Studies have shown that the main chemical components of Bamboo Ginseng are saponins, sugars, amino acids, volatile oils, nucleosides, and inorganic salts, etc., which have anti-inflammatory, cardiovascular and cerebrovascular protection, liver protection, anti-fatigue, immunomodulation, anti-tumor, anti-aging and many other effects. However, there are no reports on the use of Bamboo Ginseng in skin wound repair. Summary of the invention

[0006] The purpose of the present invention is to overcome the problems existing in the prior art and provide an application of a Panax notoginseng extract in the preparation of a medicine for promoting skin wound repair.

[0007] In order to achieve the above object, the present invention provides a use of a Panax notoginseng extract in preparing a medicine for promoting skin wound repair.

[0008] Preferably, the content of total saponins of Panax japonicus in the Panax japonicus extract is greater than 75%.

[0009] Preferably, the Panax japonicus extract is prepared according to the following steps:

[0010] (1) crushing and sieving the bamboo joint ginseng to obtain coarse powder;

[0011] (2) extracting the crude powder by heating with an ethanol solution having a volume concentration of 50 to 70% to obtain an extract;

[0012] (3) removing ethanol from the extract, adding water, and centrifuging to obtain a supernatant;

[0013] (4) extracting the supernatant with n-butanol to obtain an extract;

[0014] (5) removing n-butanol from the extract to obtain a thick extract;

[0015] (6) The thick extract is mixed with an ethanol solution having a volume concentration of 80 to 90%, the obtained mixed solution is mixed with acetone, and then allowed to stand and centrifuged, and the obtained precipitate is washed and dried.

[0016] Preferably, in step (1), the particle size of the coarse powder is 20 to 40 meshes.

[0017] Preferably, in step (2), the mass ratio of the coarse powder to the ethanol solution with a volume concentration of 50 to 70% is 1:5 to 15.

[0018] Preferably, in step (2), the temperature of the heating extraction is 40 to 80°C.

[0019] Preferably, in step (2), the volume concentration of the ethanol solution is 60%.

[0020] Preferably, in step (6), the volume ratio of the mixed solution to acetone is 1:4-5.

[0021] Preferably, the drug is in the form of powder, patch, cream or ointment.

[0022] Preferably, the drug further contains pharmaceutically acceptable excipients.

[0023] Preferably, the auxiliary material comprises one or more of a chelating agent, a surfactant, a thickener, an excipient and a stabilizer.

[0024] The present invention provides a new use of a Panax notoginseng extract in preparing a drug for promoting skin wound repair, and provides a new natural drug for treating skin wounds. Test results show that the Panax notoginseng extract can promote the healing of acute skin wounds by anti-inflammatory, accelerating the production of collagen in skin lesions, and promoting the proliferation and migration of keratinocytes. Therefore, the drug with the Panax notoginseng extract as an active ingredient has a good therapeutic effect on skin wounds. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 It is the wound healing status at different periods after skin trauma in mice;

[0026] Figure 2 This is the result of HE staining and Masson staining to detect the changes in the wounds of mice in different treatment groups;

[0027] Figure 3 This is a graph showing the effect of Panax notoginseng extract on the expression of collagen-related proteins in mouse skin lesions;

[0028] Figure 4 This is a graph showing the effect of Panax notoginseng extract on the expression of inflammation-related proteins in mouse skin lesions;

[0029] Figure 5 is the expression level of PCNA in the epidermis of the skin of mice in different treatment groups at different periods;

[0030] Figure 6 This is a graph showing the effect of Panax japonicus extract on keratinocyte viability and cycle;

[0031] Figure 7 This is a graph showing the effect of Panax japonicus extract on the relative expression levels of cell cycle-related proteins in keratinocytes;

[0032] Figure 8 This is a graph showing the effect of Panax notoginseng extract on keratinocyte migration. DETAILED DESCRIPTION

[0033] The specific implementation of the present invention is described in detail below in conjunction with the accompanying drawings. It should be understood that the specific implementation described here is only used to illustrate and explain the present invention, and is not used to limit the present invention.

[0034] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0035] The invention provides an application of a Panax japonicus extract in preparing a medicine for promoting skin wound repair.

[0036] In the present invention, the main component of the Panax japonicus extract is Panax japonicus total saponins.

[0037] Furthermore, in the Panax japonicus extract, the content of total Panax japonicus saponins is greater than 75%, preferably greater than 80%.

[0038] Studies have found that in mammals, skin wound repair involves the following four stages: coagulation, inflammation, migration, proliferation, and remodeling. The coagulation and inflammation stage occurs 1-5 days after skin damage. Initially, the exposed collagen triggers the intrinsic and extrinsic coagulation cascades, and platelets and fibrin aggregate at the site of vascular damage to form blood clots. After skin damage, multiple cells such as inflammatory cells, fibroblasts, and keratinocytes work together to heal the wound. The cells that play a major role in the inflammatory stage are neutrophils and macrophages, which secrete various inflammatory factors, such as TNF-α, IL-6, etc., to produce an innate immune response at the wound. Appropriate inflammatory cells can accelerate wound healing during the inflammatory response period, but if a large number of inflammatory cells gather, the wound will remain in a high-inflammation stage and will be difficult to heal, thus forming a chronic inflammatory wound. Therefore, anti-inflammatory is very important in skin wound repair.

[0039] The 3rd to 10th day after injury is the proliferation phase of skin wounds, when the epidermis and dermis begin to rebuild. One of the most important aspects of wound healing is re-epithelialization, that is, during the proliferation phase, basal epidermal keratinocytes fill the wound by migration, proliferation and differentiation. Keratinocytes (HaCat), as the main cell type of the epidermis, play an important role in the wound healing process.

[0040] Dermal fibroblasts migrate to the wound site and produce new extracellular matrix (ECM) substances (collagen I and collagen III, etc.). Fibroblasts and keratinocytes interact with ECM to migrate from the edge of the wound to the center to cover the wound. Cells proliferate, migrate, and differentiate during this stage to provide a scaffold for wound repair and fill the wound gap.

[0041] Experiments show that the bamboo ginseng extract provided by the present invention can not only accelerate the deposition of collagen fibers and the generation of collagen, but also reduce the inflammatory response at the skin wound, and promote the proliferation and migration of skin keratinocytes. Therefore, the bamboo ginseng extract can promote each stage of skin wound repair and has a good repair effect on acute skin wounds. In addition, the bamboo ginseng extract is derived from bamboo ginseng, has good safety, and has good biocompatibility and absorbability.

[0042] In a specific embodiment, the Panax notoginseng extract is prepared according to the following steps:

[0043] (1) crushing and sieving the bamboo joint ginseng to obtain coarse powder;

[0044] (2) extracting the crude powder by heating with an ethanol solution having a volume concentration of 50 to 70% to obtain an extract;

[0045] (3) removing ethanol from the extract, adding water, and centrifuging to obtain a supernatant;

[0046] (4) extracting the supernatant with n-butanol to obtain an extract;

[0047] (5) removing n-butanol from the extract to obtain a thick extract;

[0048] (6) The thick extract is mixed with an ethanol solution having a volume concentration of 80 to 90%, the obtained mixed solution is mixed with acetone, and then allowed to stand and centrifuged, and the obtained precipitate is washed and dried.

[0049] In a preferred embodiment, in step (1), the particle size of the coarse powder is 20 to 40 meshes.

[0050] In a preferred embodiment, in step (2), the volume ratio of the coarse powder to the ethanol solution with a volume concentration of 50-70% is 1:5-15. Specifically, the volume ratio can be, for example, 1:5, 1:6, 1:7, 1:10, 1:12, 1:13, 1:14 or 1:15, and most preferably 1:10.

[0051] In a specific embodiment, in step (2), the volume concentration of the ethanol solution can be 50%, 55%, 60%, 65% or 70%. Most preferably, the volume concentration of the ethanol solution is 60%, i.e., 60% ethanol solution.

[0052] In a specific embodiment, in step (2), the temperature of the heating extraction is 40 to 80°C, preferably 50 to 70°C.

[0053] The present invention does not limit the specific method of removing ethanol from the extract in step (3), which may be a conventional method in the art. In a specific embodiment, the ethanol in the extract is removed by evaporation under reduced pressure.

[0054] The present invention does not limit the specific method for removing the n-butanol in the extract in step (5), which may be a conventional method in the art. In a specific embodiment, the n-butanol in the extract is removed by evaporation under reduced pressure.

[0055] In a preferred embodiment, in step (6), the volume ratio of the mixed liquid to acetone is 1:4-5.

[0056] In a specific embodiment, in step (6), the volume concentration of the ethanol solution can be 80%, 85%, 87%, 88% or 90%. Most preferably, the volume concentration of the ethanol solution is 85%, that is, 85% ethanol solution.

[0057] In the present invention, the treatment method of the medicine is an external treatment method.

[0058] In the present invention, the dosage form of the drug is a powder, a patch, a cream or an ointment. The drugs in the above-mentioned various dosage forms can be prepared according to conventional methods in the pharmaceutical field, and are not specifically limited here. In addition, the dosage form of the drug is not limited thereto, and those skilled in the art believe that feasible dosage forms are within the scope of protection of the present invention.

[0059] In a specific embodiment, the drug further contains pharmaceutically acceptable excipients. The excipients may be flavoring agents or materials used in the preparation process, such as diluents, excipients, fillers, adhesives, chelating agents, stabilizers, wetting agents, disintegrants, absorption accelerators, surfactants, thickeners, adsorption carriers, and lubricants.

[0060] In a preferred embodiment, the auxiliary material includes one or more of a chelating agent, a surfactant, a thickener, an excipient and a stabilizer.

[0061] The present invention will be described in detail below by way of examples, but the protection scope of the present invention is not limited thereto. The experimental methods in the following examples, unless otherwise specified, are conventional methods in the art. The experimental materials used in the following examples, unless otherwise specified, are all commercially available.

[0062] In the following embodiments, the source of the Japonica ginseng was the dried rhizomes of Japonica ginseng collected from the Japonica ginseng planting base in Chunmuying, Xuanen County, Enshi City, Hubei Province.

[0063] In the following examples, normal temperature refers to 25±2°C.

[0064] Example 1

[0065] (1) crushing and sieving the bamboo joint ginseng to obtain a coarse powder with a particle size of 20 to 40 mesh;

[0066] (2) mixing the crude powder with a 60% ethanol solution (the mass ratio of the crude powder to the ethanol solution is 1:10), soaking for 2 hours, heating and refluxing at 50° C. for extraction for 3 times, each time for 3 hours, and combining the extracts;

[0067] (3) the extract obtained in step (2) is decompressed to recover the solvent until there is no alcohol taste, diluted with water, and then allowed to stand, centrifuged, and a supernatant is obtained;

[0068] (4) extracting the supernatant with an equal amount of aqueous n-butanol three times, and combining the extracts;

[0069] (5) recovering the solvent from the extract obtained in step (4) under reduced pressure until no n-butanol is distilled out to obtain a thick extract;

[0070] (6) The thick extract was fully dissolved in 85% ethanol solution to obtain a mixed solution, and then 4 times the volume of acetone was slowly added to the mixed solution, stirred for a while, and allowed to stand at room temperature for 4 hours to allow the precipitation to separate completely, centrifuged, and the precipitate was collected, and then washed with an appropriate amount of acetone and dried with hot air (70°C) to obtain a Panax notoginseng extract, recorded as TSPJ.

[0071] After testing, the content of total saponins in the Panax notoginseng extract was 83.48%.

[0072] Example 2

[0073] (1) crushing and sieving the bamboo joint ginseng to obtain a coarse powder with a particle size of 20 to 40 mesh;

[0074] (2) mixing the crude powder with a 60% ethanol solution (the mass ratio of the crude powder to the ethanol solution is 1:8), soaking for 2 hours, heating and refluxing at 60° C. for extraction for 3 times, each time for 3 hours, and combining the extracts;

[0075] (3) the extract obtained in step (2) is decompressed to recover the solvent until there is no alcohol taste, diluted with water, and then allowed to stand, centrifuged, and a supernatant is obtained;

[0076] (4) extracting the supernatant with an equal amount of aqueous n-butanol three times, and combining the extracts;

[0077] (5) recovering the solvent from the extract obtained in step (4) under reduced pressure until no n-butanol is distilled out to obtain a thick extract;

[0078] (6) The thick extract was fully dissolved in 85% ethanol solution to obtain a mixed solution, and then 4.5 times the volume of acetone was slowly added to the mixed solution, stirred for a while, and allowed to stand at room temperature for 5 hours to allow the precipitation to separate completely, centrifuged, and the precipitate was collected, and then washed with an appropriate amount of acetone, and dried with hot air (80°C) to obtain a Panax japonicus extract.

[0079] Example 3

[0080] (1) crushing and sieving the bamboo joint ginseng to obtain a coarse powder with a particle size of 20 to 40 mesh;

[0081] (2) mixing the crude powder with a 60% ethanol solution (the mass ratio of the crude powder to the ethanol solution is 1:12), soaking for 2 hours, heating and refluxing at 70° C. for extraction for 3 times, each time for 3 hours, and combining the extracts;

[0082] (3) the extract obtained in step (2) is decompressed to recover the solvent until there is no alcohol taste, diluted with water, and then allowed to stand, centrifuged, and a supernatant is obtained;

[0083] (4) extracting the supernatant with an equal amount of aqueous n-butanol three times, and combining the extracts;

[0084] (5) recovering the solvent from the extract obtained in step (4) under reduced pressure until no n-butanol is distilled out to obtain a thick extract;

[0085] (6) The thick extract was fully dissolved in 85% ethanol solution to obtain a mixed solution, and then 5 times the volume of acetone was slowly added to the mixed solution, stirred for a while, and allowed to stand at room temperature for 4 hours to allow the precipitation to separate completely, centrifuged, and the precipitate was collected, and then washed with an appropriate amount of acetone, and dried with hot air (60°C) to obtain a Panax japonicus extract.

[0086] Test Case

[0087] The following uses the Panax notoginseng extract obtained in Example 1 as an example to illustrate the repairing effect and mechanism of the Panax notoginseng extract of the present invention on skin wounds.

[0088] 1. Experimental Materials

[0089] 1.1 Experimental Animals

[0090] 64 6-8 week old SPF-grade BALB / c male mice were purchased from Beijing Huafukang Biotechnology Co., Ltd. and housed in the Experimental Animal Center of Three Gorges University with animal license number SCXK (Beijing) 2019-0008. The mice were kept on a 12 h day and night cycle, with free access to drinking water, and maintained at a temperature of (22 ± 2) °C and a humidity of (60 ± 5)%, and were adaptively fed for one week.

[0091] 1.2 Drugs and Reagents

[0092] The extract of Panax notoginseng obtained by extraction in Example 1 (referred to as TSPJ);

[0093] Collagen I was purchased from Wanlei Biological, with the catalog number WL0088;

[0094] Collagen III was purchased from Wanlei Biotechnology with the catalog number WL03186;

[0095] IL 6 was purchased from Wanlei Biological, catalog number WL02841;

[0096] TNFα was purchased from Santa Cruz, catalog number SC-52746;

[0097] IL-1β was purchased from abcam, catalog number ab9722;

[0098] CDK 1 was purchased from Wanlei Biotechnology with the catalog number WL02373;

[0099] CDK2 was purchased from Wanlei Biotechnology with the catalog number 02028;

[0100] Cyclin A was purchased from Wanlei Biological, catalog number WL01841;

[0101] Cyclin B was purchased from Wanlei Biological, catalog number WL02310;

[0102] β-Actin was purchased from Servicebio, catalog number GB11001;

[0103] ECL developer was purchased from Servicebio;

[0104] The BCA protein quantification kit was purchased from Beijing Pulilai Gene Technology Co., Ltd.

[0105] 2. Grouping and Dosing

[0106] A total of 64 SPF BALB / c male mice aged 6-8 weeks were randomly divided into 4 groups according to the random number table method: Normal group, Vehicle group, TSPJL group (low-dose group of Panax notoginseng extract, 25 mg / kg), and TSPJH group (high-dose group of Panax notoginseng extract, 50 mg / kg).

[0107] Grouping: Vehicle group, TSPJL group and TSPJH group Full-thickness skin excision was performed to establish a skin injury model in mice (a punch with a diameter of 8 mm was used to leave a mark on the back, the skin was cut off along the mark with a scalpel, and the photo was taken).

[0108] Drug administration: Panax notoginseng ointment (a mixture of Panax notoginseng extract and excipients) was applied to the injured skin on the back of the TSPJ L group and the TSPJ H group. The TSPJ L group applied Panax notoginseng extract at a dose of 25 mg / kg / d, and the TSPJ H group applied Panax notoginseng extract at a dose of 50 mg / kg / d. The Normal group and the Vehicle group were applied with the same amount of excipients on the back. Each group was given normal feed and drinking water.

[0109] Animal treatment: 4 mice in each group were killed on days 3, 7, and 11 after treatment, and the remaining mice were killed on day 15 to obtain skin tissue for HE, Masson staining and other technical means to observe changes in indicators. The tissue at the edge of the wound was divided into two parts, half of which was fixed in 4% paraformaldehyde, and the other half was quickly frozen in liquid nitrogen and then transferred to -80℃ for storage for later use.

[0110] 3. Statistical analysis

[0111] ImageJ software was used to scan the immunofluorescence images and Western blot bands, and Graph PadPrism 5 software was used to analyze the data. All data were expressed as x±SEM. One-way analysis of variance was used for comparison among the groups, and P<0.05 was considered statistically significant.

[0112] 4. Test items and results

[0113] 4.1. Visual observation of mouse skin

[0114] Photos were taken to observe wound healing (wound diameter was measured with a steel ruler) at 0, 3, 7, and 11 days after treatment, and Image J was used to calculate the wound healing area. The results are shown in the figure. Figure 1 As shown ( Figure 1 In the figure, A: intuitive diagram of wound healing in mice at different stages; B: statistical diagram of wound healing area in mice at different stages).

[0115] Depend on Figure 1 A shows that, in general, the wound healing area of ​​each group of mice gradually increased with the extension of time; the wound healing speed of the TSPJH group of mice was the fastest, followed by the TSPJL group, and the Vehicle group had the slowest wound healing speed. Figure 1 B shows that on the 11th day, the wound healing rate of mice in the TSPJH group was basically healed, and the wound healing rate of mice in the Vehicle group was significantly lower than that of the TSPJL group and the TSPJH group on days 3, 7, and 11. The above differences were statistically significant.

[0116] 4.2 HE staining and Masson staining of mouse skin lesions

[0117] (1) Test method

[0118] HE staining: The fixed skin tissues of mice in each group were obtained, routinely dehydrated, embedded, and sliced. The skin tissue sections were HE stained using standard procedures, and the morphological changes of the skin tissues were observed under a light microscope.

[0119] Masson staining: The fixed skin tissues of mice in each group were obtained, routinely dehydrated, embedded, and sliced. The skin tissue sections were subjected to Masson staining using standard procedures, and the changes in collagen fibers in the skin tissues were observed under a light microscope.

[0120] (2) Test results

[0121] HE staining and Masson staining were used to detect the changes in the wounds of mice in different treatment groups. Figure 2 shown. Figure 2 In the figure, A: HE staining was used to detect the wound healing of mice in different treatment groups; B: Masson staining was used to detect the changes in collagen deposition in the wounds of mice in different treatment groups; C: Masson staining was used to detect the statistical analysis of collagen deposition in mice at different periods.

[0122] Depend on Figure 2 A It can be seen that on the 7th day, the tissues of each group healed toward the center of the wound and also formed scabs. The wounds of mice in the TSPJH group healed faster and the granulation tissue grew more, followed by the TSPJL group. The mice in the Vehicle group healed the slowest toward the center and had the slowest growth of granulation tissue. At the same time, the scab formation of mice in the TSPJH and TSPJL groups was also better. On the 15th day, the tissues of each group had completed epithelialization. Compared with the Vehicle group, the mice in the TSPJH group recovered better and healed the fastest toward the center. The accessory organs on the skin, such as sebaceous glands and hair follicles, also grew more and better, and the regenerated epidermis was thinner than that of the Vehicle group; the TSPJL group was second. Figure 2 B and Figure 2 C shows that on the 7th, 11th, and 15th days after treatment, the wound surface of the TSPJH group contained the most blue-stained collagen fibers, followed by the collagen fibers of the TSPJL group, and the least in the Vehicle group. The collagen fibers of each group gradually increased over time. The above results are all statistically significant. This phenomenon suggests that the extract of Panax japonicus can accelerate the process of wound healing by accelerating the deposition of collagen fibers.

[0123] 4.3 Effects of Panax notoginseng extract on collagen-related proteins Collagen Ⅰ and Collagen Ⅲ in mouse skin lesions

[0124] (1) Test method

[0125] Western blot was used to detect the expression of collagen (Collagen Ⅰ and Collagen Ⅲ).

[0126] The specific steps are as follows: weigh 15-20 mg of mouse wound skin tissue, add lysis buffer, homogenize, lyse on ice for 1 hour, centrifuge to obtain supernatant, determine protein concentration by BCA method, add 5× loading buffer and place in boiling water bath, heat denature for 10 minutes to obtain sample. The obtained sample is subjected to electrophoresis, transferred to membrane, blocked with 5% skim milk, incubated with primary antibody at 4℃ for 12-18 hours, washed, incubated with secondary antibody at room temperature for 1 hour, developed with ultrasensitive ECL developer, and analyzed with Image J software.

[0127] (2) Test results

[0128] Effects of Panax notoginseng extract on the expression of collagen-related proteins in mouse skin lesions (n=3) Figure 3 shown. Figure 3 In the figure, A: represents the relative expression level of Collagen I in skin lesions at 7d, 11d and 15d; B: represents the relative expression level of Collagen III in skin lesions at 7d, 11d and 15d; Figure 3 In the example, col refers to Collagen.

[0129] Depend on Figure 3 It can be seen that the Western blot results showed that the expression of CollagenⅠ and CollagenⅢ in the TSPJH group and TSPJL group was higher than that in the Vehicle group at 7d, 11d and 15d. This suggests that the extract of Panax japonicus can accelerate the production of collagen and promote wound healing.

[0130] 4.4 Effects of Panax notoginseng extract on inflammatory-related proteins TNFα, IL-6 and IL-1β in mouse skin lesions

[0131] (1) Test method

[0132] Western blot was used to detect the expression of inflammation-related proteins (TNFα, IL-6 and IL-1β) in the skin tissue of the wound. The specific steps were the same as 4.3.

[0133] (2) Test results

[0134] Effects of Panax notoginseng extract on the expression of inflammation-related proteins in skin lesions of mice (n=3) Figure 4 shown. Figure 4In the figure, A: represents the relative expression level of IL-6 in the lesional skin tissues at 3d and 7d; B: represents the relative expression level of IL-1β in the lesional skin tissues at 3d and 7d; C: represents the relative expression level of TNFα in the lesional skin tissues at 3d, 7d and 11d.

[0135] Depend on Figure 4 A and Figure 4 B shows that the results of Western blot showed that the expression of inflammatory proteins IL6 and IL-1β in the TSPJH and TSPJL groups was significantly lower than that in the Vehicle group on the 3rd day, and the expression was basically the same on the 7th day. Figure 4 C shows that on the 3rd and 7th day, the expression of TNFα in the TSPJH and TSPJL groups was significantly lower than that in the Vehicle group; and the expression on the 11th day was basically the same. These results suggest that the extract of Panax japonicus can reduce the inflammatory response at the wound more quickly and accelerate wound healing.

[0136] 4.5 Immunohistochemistry (IHC) detection of the relative expression level of PCNA in the epidermis of skin lesions

[0137] (1) Test method

[0138] Paraffin sections of mouse skin lesion tissue were placed in a 60°C oven for about 4 to 5 hours, dewaxed conventionally with xylene and gradient ethanol, and antigens were repaired under high pressure using EDTA repair solution. After blocking with 5% BSA for 1 hour, PCNA (volume ratio 1:10000) was added and incubated in a 4°C refrigerator overnight. Secondary antibodies (volume ratio 1:200) were incubated at room temperature for 1 hour. After sealing with neutral gum, the expression of samples in the skin lesions was observed under a microscope and pictures were collected.

[0139] (2) Test results

[0140] The results of PCNA expression in the epidermis of mice in different treatment groups at different stages are shown in Figure 2. Figure 5 shown.

[0141] Depend on Figure 5 It can be seen that the PCNA expression in the Vehicle group, TSPJL group, and TSPJH group increased over time, with the TSPJH group increasing the most, followed by the TSPJL group, and the Vehicle group increasing the slowest. This phenomenon suggests that the extract of Panax japonicus promotes the proliferation and growth of the epidermis.

[0142] 4.6 Effect of Panax notoginseng extract on the proliferation activity of skin keratinocytes (HaCat)

[0143] (1) Test method

[0144] The MTT method was used to detect the viability of HaCat cells. The specific steps were as follows: after digesting the cells with trypsin, the culture medium was blown evenly to a single cell suspension; 100 μl of cells of appropriate density were seeded into a 96-well plate, and 5 duplicate wells were set for each group of cells; after the cells adhered to the wall, the culture medium of different concentrations of TSPJ was replaced, and the absorbance value of each well was detected after culturing for 24 hours. 20 μl of MTT was added to each well, and the culture medium was discarded after culturing at 37°C in the dark for 4 hours, and 200 μl of DMSO was added to each well, and it was oscillated in the dark for 10 minutes to dissolve it; the absorbance value of each well was measured at 570 nm using an ELISA reader, and a cell growth curve was drawn.

[0145] The cell cycle distribution of HaCat cells in each group was analyzed by flow cytometry. The specific steps were as follows: the cells were digested with trypsin and centrifuged, then seeded into small dishes at the same density; overnight, the small dishes were replaced with culture media with TSPJ concentrations of 0 μg / ml, 100 μg / ml and 150 μg / ml (the serum content in the culture media was 10%), and after culturing for 24 hours, flow cytometry analysis was performed according to the cell cycle kit.

[0146] The relative expression level of HaCat cell cycle-related proteins was detected by Western blot. The specific steps were as follows: the cells were digested with trypsin and centrifuged and then seeded into small dishes at the same density; after overnight, the small dishes were replaced with medium containing 0μg / ml, 100μg / ml and 150μg / ml TSPJ (in which the serum content was 10%), and the cells were harvested after culturing for 24 hours. The protein concentration was determined by BCA method, and the samples were prepared after adding 5× loading buffer and placed in a boiling water bath and heated for denaturation for 10 minutes. The obtained samples were subjected to electrophoresis, transferred to membranes, blocked with 5% skim milk, incubated with primary antibodies at 4℃ for 12-18 hours, washed, incubated with secondary antibodies at room temperature for 1 hour, developed with ultrasensitive ECL developer, and analyzed by Image J software.

[0147] (2) Test results

[0148] Effects of Panax notoginseng extract on the viability and cycle of keratinocytes (HaCat) Figure 6 As shown ( Figure 6 A: MTT assay to detect the effect of Panax notoginseng extract on HaCat cell viability; B: Flow cytometry to detect the effect of Panax notoginseng extract on HaCat cell cycle); Western blot to detect the effect of Panax notoginseng extract on the relative expression level of HaCat cell cycle proteins. Figure 7 shown.

[0149] Depend on Figure 6A As can be seen, the MTT results show that when the concentration of the bamboo ginseng extract is 100μg / mL, the viability of HaCat cells increases, and the cell viability reaches the highest and statistically significant when the concentration is 150μg / mL. This phenomenon suggests that the bamboo ginseng extract may accelerate the proliferation of HaCat cells. There is a close connection between the cell cycle and cell proliferation and cell differentiation. They coordinate and regulate each other and play an important role in wound repair; Figure 6 B shows that after adding Panax notoginseng extract to HaCat cells, the proportion of G1 phase decreased, while the proportion of S and G2 phases increased.

[0150] Depend on Figure 7 It can be seen that the results of Western blot showed that the protein levels of CDK1, CDK2, Cyclin A and Cyclin B in the experimental groups with the concentration of Panax notoginseng extract of 100 μg / ml and 150 μg / ml were higher than those in the experimental group with the concentration of 0 μg / ml.

[0151] Combination Figure 6-7 It can be seen that the Panax japonicus extract of the present invention can increase the proportion of HaCat cells entering DNA replication and mitosis, thereby increasing cell growth and proliferation activity.

[0152] 4.7 Effect of Panax japonicus extract on keratinocyte (HaCat) migration

[0153] (1) Test method

[0154] Scratch test: After digesting the cells with trypsin and centrifuging, they were seeded into 6-well plates at the same density. When the cells grew to more than 90% in the 6-well plates, a 200μl pipette tip was used to scratch the 6-well plates. TSPJ culture medium with a concentration of 0μg / ml, 100μg / ml and 150μg / ml was added to the 6-well plates (the serum content in the culture medium was 2%). After culturing, the cells were observed under a microscope and photographed at 12h, 24h and 48h. The coverage area of ​​each group of cells at each time point was analyzed using image J software. The experiment was repeated 3 times for statistical analysis.

[0155] Transwell experiment: After digestion, the cells were evenly spread into the upper chamber of Transwell. After the cells adhered to the wall, the upper chamber was replaced with a culture medium containing 2% serum. The lower chamber was added with culture medium with TSPJ concentrations of 0μg / ml, 100μg / ml and 150μg / ml (the serum content in the culture medium was 2%). After culturing for 48 hours, the upper and lower culture media were aspirated, the cells were washed three times with PBS, 500μL of 4% paraformaldehyde was added to each well for half an hour, the cells were washed three times with PBS, 500μL of crystal violet was added for staining for half an hour, and the cells were washed three times with PBS. Five fields of view were randomly selected under a microscope for photographing, and the number of migrated cells was counted using ImageJ.

[0156] (2) Test results

[0157] The results of the effect of Panax japonicus extract on the migration of keratinocytes (HaCat) are as follows Figure 8 shown. Figure 8 In the figure, A: Scratch assay to detect the effect of Panax notoginseng extract on the migration of HaCat cells; B: Transwell assay to detect the effect of Panax notoginseng extract on the migration of HaCat cells.

[0158] The migration of HaCat cells was observed under a microscope and photographed at four time points (0, 12, 24, and 48 h). Figure 8 A), the photos were analyzed by image J software to obtain the scratch area covered by each group of cells at each time point and the area coverage curve was drawn based on this as the ordinate. Figure 8 A It can be seen that the migration rate of the experimental group with a concentration of 150 μg / ml of the Panax notoginseng extract was the highest at each time point, followed by the experimental group with a concentration of 100 μg / ml of the Panax notoginseng extract, and the experimental group with a concentration of 0 μg / ml of the Panax notoginseng extract had the slowest migration speed.

[0159] In the Transwell experiment, the results are as follows Figure 8 As shown in B. Figure 8 B shows that the migration ability of HaCat cells in the experimental group with 150μg / ml of Panax notoginseng extract is stronger than that in other groups, and the number of HaCat cells passing through the polycarbonate membrane is the largest; the number of HaCat cells passing through the polycarbonate membrane in the experimental group with 100μg / ml of Panax notoginseng extract is second; the number of HaCat cells passing through the polycarbonate membrane in the experimental group with 0μg / ml of Panax notoginseng extract is the smallest, and its migration ability is the weakest. These results suggest that Panax notoginseng extract can increase the migration ability of HaCat cells and thus accelerate the healing of acute skin wounds.

[0160] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.

Claims

1. Use of a Panax notoginseng extract in the preparation of a drug for promoting skin wound repair, wherein the drug can promote the deposition of collagen fibers and the production of collagen, reduce inflammatory responses, and promote the proliferation and migration of keratinocytes; The skin trauma is full-thickness acute skin trauma; in, The content of total saponins in the Panax japonicus extract is greater than 80%; The Panax japonicus extract is prepared according to the following steps: (1) crushing and sieving the bamboo joint ginseng to obtain coarse powder; (2) extracting the crude powder by heating with an ethanol solution having a volume concentration of 50 to 70% to obtain an extract; (3) removing ethanol from the extract, adding water, and centrifuging to obtain a supernatant; (4) extracting the supernatant with n-butanol to obtain an extract; (5) removing n-butanol from the extract to obtain a thick extract; (6) The thick extract is mixed with an ethanol solution having a volume concentration of 80 to 90%, the obtained mixed solution is mixed with acetone, and then allowed to stand and centrifuged, and the obtained precipitate is washed and dried.

2. The use according to claim 1, characterized in that: In step (1), the particle size of the coarse powder is 20 to 40 meshes.

3. The use according to claim 1, characterized in that: In step (2), the mass ratio of the coarse powder to the ethanol solution with a volume concentration of 50-70% is 1:5-15.

4. The use according to claim 1, characterized in that: In step (2), the temperature of heating extraction is 40 to 80°C.

5. The use according to claim 1, characterized in that: In step (2), the volume concentration of the ethanol solution is 60%.

6. The use according to claim 1, characterized in that: In step (6), the volume ratio of the mixed solution to acetone is 1:4-5.

7. The use according to claim 1, characterized in that: The dosage form of the medicine is powder, patch, cream or ointment.

8. The use according to claim 7, characterized in that: The medicine also contains pharmaceutically acceptable excipients.

9. The use according to claim 8, characterized in that: The auxiliary materials include one or more of a chelating agent, a surfactant, a thickener, an excipient and a stabilizer.

Citation Information

Patent Citations

  • Panax japonicus total saponins preparation and its applications in medicament for curing myocardial ischemia

    CN101249121A

  • Traditional Chinese medicine preparation for promoting cesarean wound healing and preparation method therefor

    CN105168941A